Allianz Asset Management GmbH Increases Stake in Teladoc Health, Inc. $TDOC

Allianz Asset Management GmbH raised its holdings in shares of Teladoc Health, Inc. (NYSE:TDOC) by 189.2% during the 3rd quarter, HoldingsChannel reports. The fund owned 1,619,391 shares of the health services provider’s stock after acquiring an additional 1,059,458 shares during the quarter. Allianz Asset Management GmbH’s holdings in Teladoc Health were worth $12,518,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds have also recently modified their holdings of the company. State of Wyoming raised its holdings in Teladoc Health by 2.1% in the 3rd quarter. State of Wyoming now owns 79,075 shares of the health services provider’s stock worth $611,000 after purchasing an additional 1,628 shares during the period. AlphaQuest LLC increased its position in Teladoc Health by 119.7% in the third quarter. AlphaQuest LLC now owns 71,056 shares of the health services provider’s stock worth $549,000 after buying an additional 38,715 shares in the last quarter. Federated Hermes Inc. raised its stake in shares of Teladoc Health by 0.5% in the third quarter. Federated Hermes Inc. now owns 307,700 shares of the health services provider’s stock worth $2,379,000 after buying an additional 1,450 shares during the period. Hussman Strategic Advisors Inc. purchased a new position in shares of Teladoc Health during the 3rd quarter valued at about $1,136,000. Finally, Mitsubishi UFJ Trust & Banking Corp grew its stake in shares of Teladoc Health by 10.5% during the 3rd quarter. Mitsubishi UFJ Trust & Banking Corp now owns 138,474 shares of the health services provider’s stock valued at $1,070,000 after acquiring an additional 13,159 shares during the period. Institutional investors own 76.82% of the company’s stock.

Insider Transactions at Teladoc Health

In other news, insider Fernando M. Rodrigues sold 4,209 shares of Teladoc Health stock in a transaction dated Wednesday, December 3rd. The stock was sold at an average price of $7.48, for a total value of $31,483.32. The sale was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, insider Carlos Nueno sold 3,897 shares of the business’s stock in a transaction dated Tuesday, December 2nd. The stock was sold at an average price of $7.49, for a total value of $29,188.53. Following the completion of the sale, the insider owned 27,175 shares in the company, valued at $203,540.75. This represents a 12.54% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last three months, insiders have sold 33,288 shares of company stock worth $251,684. 0.58% of the stock is currently owned by company insiders.

Teladoc Health Stock Performance

TDOC opened at $5.02 on Monday. The company has a debt-to-equity ratio of 0.71, a quick ratio of 2.60 and a current ratio of 2.70. The stock has a market capitalization of $890.91 million, a price-to-earnings ratio of -3.92 and a beta of 2.12. The company has a fifty day moving average of $6.81 and a 200 day moving average of $7.47. Teladoc Health, Inc. has a fifty-two week low of $4.70 and a fifty-two week high of $15.21.

Analyst Ratings Changes

A number of research firms have commented on TDOC. Zacks Research cut shares of Teladoc Health from a “strong-buy” rating to a “hold” rating in a research note on Monday, November 10th. Barclays began coverage on shares of Teladoc Health in a research note on Tuesday, December 9th. They issued an “equal weight” rating and a $8.50 price objective for the company. Citigroup lowered their target price on shares of Teladoc Health from $10.00 to $9.00 and set a “neutral” rating on the stock in a research note on Friday, January 9th. Bank of America dropped their target price on shares of Teladoc Health from $9.00 to $8.00 and set a “neutral” rating for the company in a report on Tuesday, November 25th. Finally, BMO Capital Markets initiated coverage on Teladoc Health in a report on Thursday, November 13th. They set a “market perform” rating and a $8.00 price target on the stock. Three analysts have rated the stock with a Buy rating, twelve have given a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, Teladoc Health has a consensus rating of “Hold” and an average price target of $9.12.

Teladoc Health Company Profile

Teladoc Health, Inc is a leading global provider of virtual healthcare services, offering on-demand medical consultations via phone, video, and mobile app platforms. The company connects patients with licensed physicians and specialists for non-emergency medical issues, mental health support, dermatology, and chronic condition management. By leveraging digital technologies and data analytics, Teladoc aims to enhance accessibility, reduce healthcare costs, and improve patient outcomes through personalized care plans and remote monitoring.

Teladoc’s service portfolio includes general medical visits, behavioral health sessions, expert medical services for complex cases, and wellness programs designed to support chronic disease management such as diabetes, hypertension, and heart disease.